Selective targeting of HPV-16 E6/E7 in cervical cancer cells with a potent oncolytic adenovirus and its enhanced effect with radiotherapy in vitro and vivo

Cancer Letters

Volumn 291, Issue 1, 2010, Pages 67-75

  Wang, Wei ^a   Sima, Ni ^a,b   Kong, Debo ^c   Luo, Aiyue ^a   Gao, Qinglei ^a   Liao, Shujie ^a   Li, Wei ^a   Han, Lingfei ^a   Wang, Juan ^a   Wang, Shixuan ^a   Lu, Yunping ^a   Wang, Daowen ^a   Xu, Gang ^a   Zhou, Jianfeng ^a   Meng, Li ^a   Ma, Ding ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Antisense RNA; Cervical cancer; E6 E7; HPV16; Oncolytic adenovirus

Indexed keywords

COMPLEMENTARY DNA; ONCOLYTIC ADENOVIRUS; PROTEIN E6; PROTEIN E7;

ADENOVIRUS INFECTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; EMBRYO; GENE DELETION; GENE EXPRESSION REGULATION; GENE INSERTION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANIMALS; ANTISENSE ELEMENTS (GENETICS); CELL LINE, TUMOR; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; ONCOGENE PROTEINS, VIRAL; ONCOLYTIC VIROTHERAPY; PAPILLOMAVIRUS E7 PROTEINS; REPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALIA; HUMAN PAPILLOMAVIRUS TYPE 16; MUS;

EID: 77949873027     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.09.022     Document Type: Article

References (40)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55 (2005) 74-108
2. Moore D.H. Cervical cancer. Obstet. Gynecol. 107 (2006) 1152-1161
3. Petignat P., and Roy M. Diagnosis and management of cervical cancer. BMJ 335 (2007) 765-768
4. Cadron I., Van Gorp T., Amant F., Leunen K., Neven P., and Vergote I. Chemotherapy for recurrent cervical cancer. Gynecol. Oncol. 107 (2007) S113-118
5. Bischoff J.R., Kirn D.H., Williams A., Heise C., Horn S., Muna M., Ng L., Nye J.A., Sampson-Johannes A., Fattaey A., and McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274 (1996) 373-376
6. Khuri F.R., Nemunaitis J., Ganly I., Arseneau J., Tannock I.F., Romel L., Gore M., Ironside J., MacDougall R.H., Heise C., Randlev B., Gillenwater A.M., Bruso P., Kaye S.B., Hong W.K., and Kirn D.H. A controlled trial of intratumoral ONYX-015 a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6 (2000) 879-885
7. Habib N.A., Mitry R.R., Sarraf C.E., Jiao L.R., Havlik R., Nicholls J., and Jensen S.L. Assessment of growth inhibition and morphological changes in in vitro and in vivo hepatocellular carcinoma models post treatment with dl1520 adenovirus. Cancer Gene Ther. 9 (2002) 414-420
8. Hay J.G., Shapiro N., Sauthoff H., Heitner S., Phupakdi W., and Rom W.N. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral E1b-55kD gene. Hum. Gene Ther. 10 (1999) 579-590
9. Heise C., Hermiston T., Johnson L., Brooks G., Sampson-Johannes A., Williams A., Hawkins L., and Kirn D. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. 6 (2000) 1134-1139
10. Fueyo J., Gomez-Manzano C., Alemany R., Lee P.S., McDonnell T.J., Mitlianga P., Shi Y.X., Levin V.A., Yung W.K., and Kyritsis A.P. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19 (2000) 2-12
11. Ganly I., Kirn D., Eckhardt G., Rodriguez G.I., Soutar D.S., Otto R., Robertson A.G., Park O., Gulley M.L., Heise C., Von Hoff D.D., and Kaye S.B. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. 6 (2000) 798-806
12. Chen Y., DeWeese T., Dilley J., Zhang Y., Li Y., Ramesh N., Lee J., Pennathur-Das R., Radzyminski J., Wypych J., Brignetti D., Scott S., Stephens J., Karpf D.B., Henderson D.R., and Yu D.C. CV706 a prostate cancer-specific adenovirus variant in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res. 61 (2001) 5453-5460
13. Chu R.L., Post D.E., Khuri F.R., and Van Meir E.G. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin. Cancer Res. 10 (2004) 5299-5312
14. Yu D.C., Working P., and Ando D. Selectively replicating oncolytic adenoviruses as cancer therapeutics. Curr. Opin. Mol. Ther. 4 (2002) 435-443
15. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., Schiffman M.H., Moreno V., Kurman R., and Shah K.V. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. J. Natl. Cancer Inst. 87 (1995) 796-802
16. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., Snijders P.J., and Meijer C.J. Epidemiologic classification of human papillomavirus types associated with cervical cancer. New Engl. J. Med. 348 (2003) 518-527
17. Howley P.M. Role of the human papillomaviruses in human cancer. Cancer Res. 51 (1991) 5019s-5022s
18. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2 (2002) 342-350
19. Steinwaerder D.S., Carlson C.A., and Lieber A. Human papilloma virus E6 and E7 proteins support DNA replication of adenoviruses deleted for the E1A and E1B genes. Mol. Ther. 4 (2001) 211-216
20. Santin A.D., Hermonat P.L., Ravaggi A., Chiriva-Internati M., Pecorelli S., and Parham G.P. Radiation-enhanced expression of E6/E7 transforming oncogenes of human papillomavirus-16 in human cervical carcinoma. Cancer 83 (1998) 2346-2352
21. Tang X., Zhang Q., Nishitani J., Brown J., Shi S., and Le A.D. Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells. Clin. Cancer Res. 13 (2007) 2568-2576
22. Zhou J., Gao Q., Chen G., Huang X., Lu Y., Li K., Xie D., Zhuang L., Deng J., and Ma D. Novel oncolytic adenovirus selectively targets tumor-associated polo-like kinase 1 and tumor cell viability. Clin. Cancer Res. 11 (2005) 8431-8440
23. Ketner G., and Boyer J. Isolation, growth, and purification of defective adenovirus deletion mutants. Adenov. Methods Protocols (1998) 25-32
24. Sima N., Wang W., Kong D., Deng D., Xu Q., Zhou J., Xu G., Meng L., Lu Y., Wang S., and Ma D. RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53. Apoptosis 13 (2008) 273-281
25. Sima N., Wang S., Wang W., Kong D., Xu Q., Tian X., Luo A., Zhou J., Xu G., Meng L., Lu Y., and Ma D. Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells. Gynecol. Oncol. 106 (2007) 299-304
26. Pelletier A.J., Kunicki T., and Quaranta V. Activation of the integrin alpha v beta 3 involves a discrete cation-binding site that regulates conformation. J. Biol. Chem. 271 (1996) 1364-1370
27. Zhang W.W. Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther. 6 (1999) 113-138
28. Johnson L., Shen A., Boyle L., Kunich J., Pandey K., Lemmon M., Hermiston T., Giedlin M., McCormick F., and Fattaey A. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 1 (2002) 325-337
29. Everts B., and van der Poel H.G. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther. 12 (2005) 141-161
30. Gao Q., Zhou J., Huang X., Chen G., Ye F., Lu Y., Li K., Zhuang L., Huang M., Xu G., Wang S., and Ma D. Selective targeting of checkpoint kinase 1 in tumor cells with a novel potent oncolytic adenovirus. Mol. Ther. 13 (2006) 928-937
31. Chen G., Zhou J., Gao Q., Huang X., Li K., Zhuang L., Huang M., Xu G., Wang S., Lu Y., and Ma D. Oncolytic adenovirus-mediated transfer of the antisense chk2 selectively inhibits tumor growth in vitro and in vivo. Cancer Gene Ther. 13 (2006) 930-939
32. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 12 (1998) 2245-2262
33. Cam H., and Dynlacht B.D. Emerging roles for E2F: beyond the G1/S transition and DNA replication. Cancer Cell 3 (2003) 311-316
34. Matsukura T., Koi S., and Sugase M. Both episomal and integrated forms of human papillomavirus type 16 are involved in invasive cervical cancers. Virology 172 (1989) 63-72
35. Yasmeen A., Bismar T.A., Kandouz M., Foulkes W.D., Desprez P.Y., and Al Moustafa A.E. E6/E7 of HPV type 16 promotes cell invasion and metastasis of human breast cancer cells. Cell Cycle 6 (2007) 2038-2042
36. Bertelsen K., and Jakobsen A. Radiotherapy for gynecologic cancer. Curr. Opin. Oncol. 5 (1993) 885-890
37. Chen S.W., Liang J.A., Yang S.N., Hung Y.C., Yeh L.S., Shiau A.C., and Lin F.J. Radiation injury to intestine following hysterectomy and adjuvant radiotherapy for cervical cancer. Gynecol. Oncol. 95 (2004) 208-214
38. von Eschenbach A.C. A vision for the national cancer program in the United States. Nat. Rev. Cancer 4 (2004) 820-828
39. DeWeese T.L., van der Poel H., Li S., Mikhak B., Drew R., Goemann M., Hamper U., DeJong R., Detorie N., Rodriguez R., Haulk T., DeMarzo A.M., Piantadosi S., Yu D.C., Chen Y., Henderson D.R., Carducci M.A., Nelson W.G., and Simons J.W. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 61 (2001) 7464-7472
40. Yu D.C., Chen Y., Dilley J., Li Y., Embry M., Zhang H., Nguyen N., Amin P., Oh J., and Henderson D.R. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res. 61 (2001) 517-525